GRFS vs NBTX
Grifols SA and Nanobiotix S.a., side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | GRFS | NBTX |
|---|---|---|
| Revenue | €7.2B | €32.6M |
| Net income | €156.9M | €-24.0M |
| Gross margin | 38.7% | — |
| Net margin | 2.2% | −73.5% |
| Return on equity | 2.8% | — |
| Diluted EPS | €0.23 | −€0.50 |
| Dividend / share | — | — |
| Payout ratio | 0.6% | — |
| Free cash flow | €669.6M | €-34.0M |
| Equity | €5.9B | — |
| Net debt / equity | −0.42× | — |
| Current ratio | 2.66× | 1.09× |
| Revenue CAGR 5y | 7.2% | 67.0% |
| Profit CAGR 5y | −24.2% | — |
GRFS bills 221.3× the revenue of NBTX, and NBTX closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | GRFS | NBTX |
|---|---|---|
| FY2024 | €7.2B | €-7.2M |
| FY2023 | €6.6B | €36.2M |
| FY2022 | €6.1B | €4.8M |
| FY2021 | €4.9B | €2.6M |
| FY2020 | €5.3B | €2.5M |
| FY2019 | €5.1B | €2.5M |
| FY2018 | €4.5B | €3.5M |
Net income by year
Bottom line
| Fiscal year | GRFS | NBTX |
|---|---|---|
| FY2024 | €156.9M | €-68.1M |
| FY2023 | €42.3M | €-39.7M |
| FY2022 | €185.0M | €-57.0M |
| FY2021 | €188.7M | €-47.1M |
| FY2020 | €618.5M | €-33.6M |
| FY2019 | €625.1M | €-50.9M |
| FY2018 | €596.6M | €-30.3M |
Advertisement
AdSense · Rectangle 336×280